Skip to main content

Table 1 Major trials exploring bisphosphonate activity in early breast cancer

From: Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence

Trial Number of patients Regimen Duration (years) Combination therapy DFS benefit (+/−) Bone loss benefit (+/−)
Z-Fast [45] 600 Immediate versus delayed ZA 5 Letrozol NR +
ZO-FAST [46] 1,065 Immediate versus delayed ZA 5 Letrozol + +
NSAPB-34 [44] 3,323 Oral clodronate 3 Standard therapy according to stage – (population as a whole) +
AZURE [47] 3,360: premenopausal, 1,504; postmenopausal, 1,531; unknown, 324 ZA 5 Standard therapy according to stage – (but significant improvements in DFS in postmenopausal women) +
Saarto et al. [43] 299 Oral clodronate 3 Standard therapy according to stage 29 NR
NATAN [48] 693 ZA 5 Standard therapy according to stage – (trend for women aged >55) NR
  1. DFS disease-free survival, NR not reported, ZA zoledronic acid